Canakinumab for the Prevention of Progression to Cancer in Patients With Clonal Cytopenias of Unknown Significance, IMPACT Study
Abroad (travel likely)RecruitingPHASE2
Conditions
Clonal Cytopenia of Undetermined Significance
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
University of Miami, Miami, Florida, United States
Contact: Principal Investigator (Namrata S Chandhok, MD)Weill Cornell Medical College, New York, New York, United States
Contact: Principal Investigator (Pinkal Desai, M.D.)Memorial Sloan Kettering Cancer Center, New York, New York, United States
Contact: Principal Investigator (Tamanna Haque, MD)Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
Contact: Principal Investigator (Uma M. Borate, MD, MS)Vanderbilt University Medical Center, Nashville, Tennessee, United States
Contact: Principal Investigator (Ashwin Kishtagari, MD)UT Southwestern Medical Center at Dallas, Dallas, Texas, United States
Contact: Study coordinator (Silviya Meletath, MD, MBS) · silviya.meletath@utsouthwestern.edu · 909-560-9597Contact: Principal Investigator (Yazan Madanat, MD)
Study leads
Uma M Borate, MD, MS
Principal Investigator
Ohio State University Comprehensive Cancer Center